Spider Silk in BioTech

Interview with Jekaterina Romanova, founder & CEO of PrintyMed For today’s podcast, produced in association with the Women TechEU scheme, we sit down with Jekaterina Romanova, CEO and co-founder of Latvian biotech startup PrintyMed, to discuss biomimetic spider silk, its medical potential, and the challenges of scaling deep-tech innovation in Europe. The Women TechEU scheme is an EU-funded project supporting women leading deep tech startup companies from Europe. As part of the consortium team implementing the programme, our mission is to foster inclusive innovation by supporting women-led startups, including under-represented deep tech sectors and European regions. We believe that diversity drives innovation, and we are here to provide women in deep tech with more opportunities, resources, and support in order to build market-shaping companies at global level. Between 2026-2028, the current project consortium will run a continuous open call with 4 cut-off dates. Following a rigorous evaluation process, 160 total beneficiaries will be selected. Each beneficiary will receive €75k grants (non-dilutive finance), as well as a tailored package of mentorship, training, expert guidance, matchmaking and networking opportunities, and support in bridging the gap to other EIC funding and support schemes. EU-Startups is a proud member of the consortium implementing the Women TechEU Programme from 2026 to 2028. In this podcast, Jekaterina reflects on her unconventional path into biotechnology. After studying economics and working in banking, she entered entrepreneurship at 18 through a posture-correction clothing startup. She later founded a company developing 3D-printed bone grafts, gaining experience in medical regulation, funding, and commercialisation. At PrintyMed, Jekaterina leads grants, investment, partnerships, and strategy, while scientists and doctors oversee laboratory research. The company’s biomimetic spider silk technology originated at the Latvian Institute of Organic Synthesis and replicates aspects of how spiders naturally produce silk. PrintyMed’s long-term ambition is to support artificial organs and biological scaffolds. It has developed an artificial heart-valve prototype and is exploring artificial nerves, wound dressings, and regenerative medicine. Its first commercial focus is membranes for organ-on-a-chip systems, which help pharmaceutical companies and researchers test drugs while reducing animal testing. PrintyMed is already running pilot projects, although products intended for patients will require several more years of certification. Jekaterina also discusses the importance of European funding. PrintyMed has secured about €2 million in grants, including €75,000 from Women TechEU and roughly €700,000 through a European Innovation Council programme. This support strengthened the company’s expertise in regulation, intellectual property, scaling, and fundraising. The conversation also covers expansion beyond Europe. PrintyMed is building relationships in Saudi Arabia, where government-backed biotechnology initiatives, research partnerships, and certification opportunities could support international growth. Jekaterina argues that Europe’s medical-device regulations can slow innovation and calls for controlled fast-track testing environments. She also highlights spider silk’s potential in cosmetics and skincare, following discussions with Chanel about a regenerative cosmetic glove. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Innovation Council and SMEs Executive Agency (EISMEA). Neither the European Union nor the granting authority can be held responsible for them.